BioStock-article: Aptahem comments on the paused phase I study
Aptahem develops the drug candidate Apta-1 as an acute treatment of sepsis. Recently, the company announced that the ongoing phase Ia study had been temporarily paused after observing interesting data. To learn more about the significance of this data, BioStock contacted Aptahem’s CEO Mikael Lindstam.Read the full interview with Mikael Lindstam at biostock.se: https://www.biostock.se/en/2023/07/aptahem-comments-on-the-paused-phase-i-study/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA)